At 14.7% CAGR, the Middle East & Africa Bioprocess Technology Market is projected to be worth US$ 2,443.75 million by 2028, says Business Market Insights

According to Business Market Insights research, the Middle East & Africa bioprocess technology market was valued at US$ 1,233.00 million in 2023 and is expected to reach US$ 2,443.75 million by 2028, registering a CAGR of 14.7% from 2023 to 2028. Emergence of automated real‐time flow cytometry (ART‐FCM) and introducing advanced bioprocess technologies are the critical factors attributed to the Middle East & Africa bioprocess technology market expansion.               

Pharmaceutical companies are spending huge sum in R&D to introduce new molecules with Flow cytometry (FCM) and its technological possibilities have greatly advanced in the past decade as an analysis tool for single-cell properties and population distributions of different cell types in bioreactors. Along the way, a few automated real‐time flow cytometry (ART‐FCM) solutions were developed for monitoring bioreactor processes without operator interference over extended periods with a variable sampling frequency. ART‐FCM enables long‐term measurements without missing any important events in bioprocesses and uncovers temporal phenomena that are likely unknown and should be investigated in greater detail. Also, more frequent measurements can be performed at a user-defined frequency, independent of the availability of personnel. When compared with methods such as omics that are only partially available on a single-cell level, multi-parameter measurements can be easily established without the extended effort of labor and time via ART-FCM. Compared with conventional FCM studies, microfluidic devices great future potential as ART‐FCM on a chip. In this context, parallelization might become more relevant, as samples from different bioreactors or different locations inside a bioreactor setup could be analyzed simultaneously. Many aspects might also be adapted to other experimental setups where fast and reproducible real‐time monitoring of fluorescent process parameters is also of interest. In conclusion, ART‐FCM will most probably advance exponentially in the upcoming years.  

On the contrary, stringent regulatory policies hurdles the growth of Middle East & Africa bioprocess technology market.

Based on type, the Middle East & Africa bioprocess technology market is segmented into cell culture media bioprocess, chromatography bioprocess, and consumables & accessories, and others. The consumables & accessories segment held 44.8% share of Middle East & Africa bioprocess technology market in 2023, amassing US$ 552.40 million. It is projected to garner US$ 1,088.72 million by 2028 to expand at 14.5% CAGR during 2023–2028.

Based on modality, the Middle East & Africa bioprocess technology market is bifurcated into single use and multiple use. The single use segment held 85.8% share of Middle East & Africa bioprocess technology market in 2023, amassing US$ 1,057.37 million. It is projected to garner US$ 2,078.53 million by 2028 to expand at 14.5% CAGR during 2023–2028.

Based on end-use, the Middle East & Africa bioprocess technology market is segmented into academic & medical institutions, biopharmaceutical companies, research laboratories, and others. The biopharmaceutical companies segment held 61.1% share of Middle East & Africa bioprocess technology market in 2023, amassing US$ 752.95 million. It is projected to garner US$ 1,489.87 million by 2028 to expand at 14.6% CAGR during 2023–2028.  

Based on country, the Middle East & Africa bioprocess technology market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Our regional analysis states that Saudi Arabia captured 33.9% share of Middle East & Africa bioprocess technology market in 2023. It was assessed at US$ 417.37 million in 2023 and is likely to hit US$ 814.99 million by 2028, exhibiting a CAGR of 14.3% during the forecast period.  

Key players profiled in the Middle East & Africa bioprocess technology market report are Danaher Corp; Eppendorf SE; Lonza Group AG; Merck KGaA; Repligen Corp; Sartorius AG; and Thermo Fisher Scientific Inc, among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com